|
Fetal Alcohol Syndrome
|
0.300 |
Biomarker
|
disease |
PSYGENET |
Ercc6l expression in 15.5-day embryonic brain and heart, which are the most commonly affected organs of FAS, were both decreased by alcohol exposure.
|
15917148 |
2005 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
These results suggest that ERCC6L promotes the growth and invasion of CRC cells, and ERCC6L may be a potential new target for cancer therapy.
|
31289493 |
2019 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.
|
30459398 |
2019 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The expression level of ERCC6L was significantly associated with tumor size (P<0.05), but not with other clinical features, including age, gender, differentiation and clinical stage.
|
31289493 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
These results suggest that ERCC6L promotes the growth and invasion of CRC cells, and ERCC6L may be a potential new target for cancer therapy.
|
31289493 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
A short hairpin RNA ERCC6L lentivirus was constructed to investigate the role of ERCC6LR in cancer.
|
30066865 |
2018 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
A short hairpin RNA ERCC6L lentivirus was constructed to investigate the role of ERCC6LR in cancer.
|
30066865 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, our results suggest that ERCC6L may stimulates cancer cell proliferation by promoting cell cycle through a way of RAB31-MAPK-CDK2, and it could be a potential biomarker for cancer prognosis and target for cancer treatment.
|
28178669 |
2017 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The xenograft experiment showed that silencing of ERCC6L strikingly inhibited tumor growth from the 7th day after xenograft in nude mice.
|
28178669 |
2017 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, our results suggest that ERCC6L may stimulates cancer cell proliferation by promoting cell cycle through a way of RAB31-MAPK-CDK2, and it could be a potential biomarker for cancer prognosis and target for cancer treatment.
|
28178669 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Clinical samples analysis showed that PICH is highly expressed in TNBC compared to other breast cancer subtypes.
|
31160555 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Evidence indicates that ERCC6L is an indispensable component of mammalian cell mitosis, while it fails to disclose the role of ERCC6L in tumorigenesis.
|
30459398 |
2019 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Clinical samples analysis showed that PICH is highly expressed in TNBC compared to other breast cancer subtypes.
|
31160555 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The present study analyzed 106 paired breast cancer tissues from The Cancer Genome Atlas and demonstrated that excision repair cross‑complementation group 6 like (ERCC6L), a newly discovered DNA helicase, was overexpressed in 91.51% (97/106), unchanged in 7.54% (8/106) and decreased in 0.94% (1/106) of breast cancer samples.
|
30066865 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Overall, our data indicate that PICH is essential to preserve chromosomal integrity in rapidly proliferating cells and is therefore critical during embryonic development and tumorigenesis.
|
30232008 |
2018 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The present study analyzed 106 paired breast cancer tissues from The Cancer Genome Atlas and demonstrated that excision repair cross‑complementation group 6 like (ERCC6L), a newly discovered DNA helicase, was overexpressed in 91.51% (97/106), unchanged in 7.54% (8/106) and decreased in 0.94% (1/106) of breast cancer samples.
|
30066865 |
2018 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, gene expression microarray analysis followed by the validating western blot after knocking down ERCC6L expression in 786-O cells highlighted the involvement of MAPK signaling pathway in regulation of ERCC6L on cellular process of RCC.
|
30459398 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was identified that reducing ERCC6L expression using small interfering RNA significantly inhibited the proliferation and colony-forming ability of CRC cell lines.
|
31289493 |
2019 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
At the same time, RCC cells those were transfected with shRNA targeting to ERCC6L grew significantly slower than parental cells in immunodeficient mice.
|
30459398 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, gene expression microarray analysis followed by the validating western blot after knocking down ERCC6L expression in 786-O cells highlighted the involvement of MAPK signaling pathway in regulation of ERCC6L on cellular process of RCC.
|
30459398 |
2019 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
ERCC6L promotes cell growth and invasion in human colorectal cancer.
|
31289493 |
2019 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings show the dependency of TNBC cells on PICH for faithful chromosome segregation and the clinical potential of PICH inhibition to improve treatment of patients with high-risk TNBC.
|
31160555 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
ERCC6L promotes cell growth and invasion in human colorectal cancer.
|
31289493 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings show the dependency of TNBC cells on PICH for faithful chromosome segregation and the clinical potential of PICH inhibition to improve treatment of patients with high-risk TNBC.
|
31160555 |
2019 |
|
Chromophobe Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three real hub genes (SKA1, ERCC6L, GTSE-1) were selected out after mapping candidate genes to GSE15641 and two of them (SKA1, ERCC6L) were significantly related to overall survivals of ChRCC patients.
|
30564062 |
2018 |